Editorial
doi: 10.4155/fmc.12.210.
Drug discovery for breast cancer and co-instantaneous cardiovascular disease: what is the future?
- PMID: 23495679
- DOI: 10.4155/fmc.12.210
Item in Clipboard
Editorial
Drug discovery for breast cancer and co-instantaneous cardiovascular disease: what is the future?
Future Med Chem.
2013 Mar.
No abstract available
Similar articles
-
Novel targeted agents for the treatment of advanced breast cancer.Future Med Chem. 2012 May;4(7):893-914. doi: 10.4155/fmc.12.45. Future Med Chem. 2012. PMID: 22571614 Review.
-
Prevention and management of major side effects of targeted agents in breast cancer.Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e79-85. doi: 10.1016/j.critrevonc.2010.07.014. Epub 2011 Mar 15. Crit Rev Oncol Hematol. 2012. PMID: 20817545 Review.
-
Early breast cancer therapy and cardiovascular injury.J Am Coll Cardiol. 2008 Mar 25;51(12):1235; author reply 1235. doi: 10.1016/j.jacc.2007.11.060. J Am Coll Cardiol. 2008. PMID: 18355667 No abstract available.
-
Targeting mitochondrial function for the treatment of breast cancer.Future Med Chem. 2014 Sep;6(13):1499-513. doi: 10.4155/fmc.14.100. Future Med Chem. 2014. PMID: 25365234 Review.
-
Cardiovascular complications of breast cancer therapy.Clin Adv Hematol Oncol. 2008 Apr;6(4):247-8, 282. Clin Adv Hematol Oncol. 2008. PMID: 18496491 No abstract available.
Cited by
-
CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Nat Rev Urol. 2014 Jan;11(1):32-42. doi: 10.1038/nrurol.2013.274. Epub 2013 Nov 26. Nat Rev Urol. 2014. PMID: 24276076 Review.
-
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.Int J Mol Sci. 2013 Jul 4;14(7):13958-78. doi: 10.3390/ijms140713958. Int J Mol Sci. 2013. PMID: 23880851 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
